Research into the pathogenesis of psoriasis, as highlighted in the recently published Part I of the theme issue on psoriasis, has contributed greatly to the rational development of new treatment options. The development of interleukin-12/23-directed agents, such as ustekinumab, which has been tested in phase III clinical trials, may serve as a prominent example to illustrate this point. On the other hand, the deeper knowledge of pathogenic pathways in the psoriatic disease process has illuminated the mode of action of empirically established treatment options, such as phototherapies.
展开▼
